TY  - BOOK
AU  - Desai, Sanjal
AU  - Kim, Chul
AU  - Veytsman, Irina
TI  - Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?. [Review]
SN  - 1523-3790
PY  - 2019///
KW  - *Carcinoma, Non-Small-Cell Lung/dt [Drug Therapy]
KW  - *Lung Neoplasms/dt [Drug Therapy]
KW  - *Protein Kinase Inhibitors/tu [Therapeutic Use]
KW  - Antineoplastic Agents/pd [Pharmacology]
KW  - Antineoplastic Agents/tu [Therapeutic Use]
KW  - Carcinoma, Non-Small-Cell Lung/en [Enzymology]
KW  - Carcinoma, Non-Small-Cell Lung/ge [Genetics]
KW  - Carcinoma, Non-Small-Cell Lung/pa [Pathology]
KW  - Clinical Trials as Topic
KW  - ErbB Receptors/ai [Antagonists & Inhibitors]
KW  - ErbB Receptors/ge [Genetics]
KW  - Humans
KW  - Lung Neoplasms/en [Enzymology]
KW  - Lung Neoplasms/ge [Genetics]
KW  - Lung Neoplasms/pa [Pathology]
KW  - Molecular Targeted Therapy/mt [Methods]
KW  - Mutation
KW  - Neoplasm Staging
KW  - Protein Kinase Inhibitors/pd [Pharmacology]
KW  - Randomized Controlled Trials as Topic
KW  - Washington Cancer Institute
KW  - Journal Article
KW  - Review
N2  - PURPOSE OF REVIEW: Identification of targetable mutations such as EGFR has allowed opportunity for Tyrosine Kinase Inhibitor (TKI) therapy for lung cancer treatment. EGFR-TKIs have revolutionized treatment of advanced EGFR mutant Non-Small Cell Lung Cancer (NSCLC), but there is little evidence that EGFR-TKI treatment is effective in stage III NSCLC. Here we discuss recent evidence supporting the use of EGFR-TKI therapy in combination with chemotherapy and radiation in stage III NSCLC; RECENT FINDINGS: Recent results of small trials testing EGFR-TKI therapy in combination with chemoradiation showed promising efficacy, improved outcomes, and a tolerable toxicity profile when administered to patients with EGFR mutant stage III NSCLC. However, strong supporting evidence regarding EGFR-TKI therapy in stage III NSCLC is lacking because previous trials involved a small patient population or were terminated due to slow participant accrual. Despite the lack of large randomized clinical trials, results from early-stage trials highlight promising future directions for investigating the use of EGFR-TKI therapy in stage III NSCLC treatment
UR  - https://dx.doi.org/10.1007/s11912-019-0835-x
ER  -